The combined efficacy of MEDICA analogs in treating diabetes, while mimicking (n-3) PUFA activity in suppressing HNF-4α transcriptional activity [15, 20], prompted our interest in probing their efficacy in suppressing carcinogen-induced diabetes-promoted CRC. Here, HNF4A is linked to diabetes mellitus.